You are here: Industry Insights > PSA

News List

Cosentyx gains EU approval for new label extension pharmatimes
March 03, 2021
Novartis’ interleukin (IL)-17A inhibitor Cosentyx has gained an EU label update to include data for axial manifestations of psoriatic arthritis (PsA).
AbbVie's Rinvoq bags two new EU approvals pharmatimes
January 27, 2021
The European Commission (EC) has approved AbbVie’s Rinvoq (upadacitinib) for the treatment of active psoriatic arthritis (PsA) and active ankylosing spondylitis (AS).
Janssen's Tremfya approved for active psoriatic arthritis pharmatimes
November 27, 2020
The European Commission has approved Janssen’s Tremfya (guselkumab) as a first-in-class treatment for active psoriatic arthritis (PsA).
Doubt Over Long-Term Use of Hormone Rx for Recurrent Prostate Cancer drugs
September 18, 2019
Running contrary to current guidelines, new research suggests that use of hormone-suppressing treatment over the long term may not help some men battling recurrent prostate cancer, and may even cause harm.
FDA approves the inclusion of new evidence for Cosentyx in PsA europeanpharmaceuticalreview
April 25, 2019
The FDA has approved the inclusion of new evidence that Cosentyx significantly slows the progression of joint structural damage...
Sandoz Canada receives Health Canada approval for Erelzi (etanercept) in the Treatment of Psoriatic Arthritis (PsA) in Adult Patients firstwordpharma
January 22, 2019
Erelzi is the only etanercept biosimilar to be indicated for reducing the signs and symptoms of psoriatic arthritis (PsA) in adult patients.
Sandoz Canada receives Health Canada approval for Erelzi (etanercept) in the Treatment of Psoriatic Arthritis (PsA) in Adult Patients firstwordpharma
January 22, 2019
Erelzi is the only etanercept biosimilar to be indicated for reducing the signs and symptoms of psoriatic arthritis (PsA) in adult patients.
Sophiris slides on prostate cancer data but vows to press on fiercebiotech
December 25, 2018
Sophiris Bio is adamant that it will advance its lead drug topsalysin into phase 3 testing, after a second dose showed no additional benefit in a prostate cancer trial.....
Lilly's Taltz beats out AbbVie's megadrug Humira in psoriatic arthritis showdown fiercepharma
December 19, 2018
What’s a surefire way to get noticed in any field? Beat out a behemoth. And that’s what Eli Lilly’s Taltz has just done in psoriatic arthritis (PsA).
Novartis Receives Approval for Cosentyx Label Update in Europe americanpharmaceuticalreview
October 30, 2018
Novartis Receives Approval for Cosentyx Label Update in Europe

Previous page 1 2 3 Next page